tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Outlook Therapeutics Completes FDA Meeting on ONS-5010
PremiumCompany AnnouncementsOutlook Therapeutics Completes FDA Meeting on ONS-5010
2M ago
Outlook Therapeutics says plans to resubmit BLA before end of CY25
Premium
The Fly
Outlook Therapeutics says plans to resubmit BLA before end of CY25
2M ago
Outlook Therapeutics says had ‘productive’ discussion with FDA
Premium
The Fly
Outlook Therapeutics says had ‘productive’ discussion with FDA
2M ago
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
3M ago
FDA Issues Complete Response Letter to Outlook Therapeutics
Premium
Company Announcements
FDA Issues Complete Response Letter to Outlook Therapeutics
3M ago
Outlook Therapeutics submits Type A meeting request to FDA
Premium
The Fly
Outlook Therapeutics submits Type A meeting request to FDA
3M ago
Outlook CRL ‘a significant setback,’ doesn’t mean end for Lytenava, says Chardan
PremiumThe FlyOutlook CRL ‘a significant setback,’ doesn’t mean end for Lytenava, says Chardan
3M ago
Outlook Therapeutics downgraded to Neutral from Buy at Guggenheim
Premium
The Fly
Outlook Therapeutics downgraded to Neutral from Buy at Guggenheim
3M ago
Outlook Therapeutics’ resubmission for wet AMD candidate rejected by FDA
Premium
The Fly
Outlook Therapeutics’ resubmission for wet AMD candidate rejected by FDA
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100